Exelixis Delivers Additional Cancer Targets To Protein Design Labs.(Brief Article)

2001 DEC 25 - (NewsRx.com & NewsRx.net) -- Exelixis, Inc., has delivered five additional cancer antibody targets to Protein Design Labs, Inc., (PDL) in the companies' ongoing oncology collaboration.

The collaboration, signed in May 2001, utilizes Exelixis' expertise in target identification and validation to discover novel antibody targets, and PDL's proficiency in antibody clinical development and manufacturing to create humanized antibodies for the diagnosis, prevention and treatment of cancer.

The targets delivered to and accepted by PDL have met a number of stringent criteria that Exelixis applies to all of its targets prior to initiating drug discovery. …